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CONTEXT AND OBJECTIVE: Scientific and technological development is crucial for advancing the Brazil-
ian health system and for promoting quality of life. The way in which the Brazilian Ministry of Health has 
supported clinical research to provide autonomy, self-sufficiency, competitiveness and innovation for the 
healthcare industrial production complex, in accordance with the National Policy on Science, Technology 
and Innovation in Healthcare, was analyzed.  
DESIGN AND SETTING: Descriptive investigation, based on secondary data, conducted at the Depart-
ment of Science and Technology, Ministry of Health.  
METHODS: The Ministry of Health’s research management database, PesquisaSaúde, was analyzed from 
2002 to 2009, using the key word “clinical research” in the fields “primary sub-agenda” or “secondary sub-
agenda”. The 368 projects retrieved were sorted into six categories: basic biomedical research, preclinical 
studies, expanded clinical research, clinical trials, infrastructure support and health technology assessment. 
From a structured review on “clinical research funding”, results from selected countries are presented and 
discussed. 
RESULTS: The amount invested was R$ 140 million. The largest number of projects supported “basic bio-
medical research”, while the highest amounts invested were in “clinical trials” and “infrastructure support”. 
The southeastern region had the greatest proportion of projects and financial resources. In some respects, 
Brazil is ahead of other BRICS countries (Russia, India, China and South Africa), especially with regard to 
establishing a National Clinical Research Network. 
CONCLUSION: The Ministry of Health ensured investments to encourage clinical research in Brazil and 
contributed towards promoting cohesion between investigators, health policies and the healthcare in-
dustrial production complex. 
rESumo
CONTEXTO E OBJETIVO: O desenvolvimento científico e tecnológico é crucial para avançar o Sistema 
Único de Saúde e promover qualidade de vida. Analisou-se como o Ministério da Saúde (MS) apoiou a 
pesquisa clínica para proporcionar autonomia, auto-suficiência, competitividade e inovação no complexo 
industrial produtivo da saúde, segundo a Política Nacional de Ciência, Tecnologia e Inovação em Saúde. 
TIPO DE ESTUDO E LOCAL: Estudo descritivo baseado em dados secundários, realizado no Departamen-
to de Ciência e Tecnologia, Ministério da Saúde. 
MÉTODOS: O banco de dados gerencial de pesquisas do MS, PesquisaSaúde, foi analisado de 2002 a 
2009, empregando a palavra chave “pesquisa clínica” nos campos “sub-agenda principal” ou “sub-agenda 
secundária”. Foram encontrados 368 projetos, classificados em seis categorias: pesquisa biomédica básica, 
estudos pré-clínicos, pesquisa clínica expandida, ensaios clínicos, infraestrutura e avaliação de tecnologias 
em saúde. A partir da revisão estruturada sobre “financiamento da pesquisa clínica”, resultados de países 
selecionados são apresentados e discutidos.   
RESULTADOS: O total investido foi R$ 140 milhões. A maioria dos projetos apoiou “pesquisa biomédica 
básica” e os maiores investimentos foram em “ensaios clínicos” e projetos de “infra-estrutura”. O Sudeste 
deteve a maior proporção de projetos e recursos financeiros. Em alguns aspectos, o Brasil está à frente 
de outros países do BRICS (Rússia, Índia, China e África do Sul), sobretudo no estabelecimento da Rede 
Nacional de Pesquisa Clínica. 
CONCLUSÃO: O MS assegurou investimentos para incentivar a pesquisa clínica no Brasil, contribuindo 
para promover a coesão entre os investigadores, as políticas de saúde e o complexo industrial da saúde.
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INTRODUCTION
Scientific and technological development, guided by standards of 
excellence, ethics and equity, is crucial for advancing the Brazil-
ian Unified Health System (Sistema Único de Saúde, SUS) and 
for improving quality of life. Article 200, paragraph V of the Bra-
zilian Constitution describes one of the missions of SUS as “to 
increase scientific and technological development in its area of 
operation”.1 Integration between government activities, universi-
ties and businesses in the modern systems of science, technology 
and innovation that exist in industrialized countries has virtu-
ally eliminated the gap between discovery and application. This 
has also created a “virtuous circle” of positive feedback between 
research and development and socioeconomic status.2 
OBJECTIVE
This article aimed to analyze how the Brazilian Ministry of 
Health (Ministério da Saúde, MS) has supported national clinical 
research to provide technological training, autonomy and self-
sufficiency, competitiveness and innovation for the healthcare 
industrial production complex, in accordance with the National 
Policy on Science, Technology and Innovation in Healthcare. 
The National Agenda of Priorities in Healthcare Research 
Between 2002 and 2009, the Department of Science and Tech-
nology (Departamento de Ciência e Tecnologia, Decit) of the 
Secretariat of Science, Technology and Strategic Inputs, at the 
Ministry of Health, invested almost R$ 693 million to support 
healthcare research and development. These figures are incre-
mental to those coming from other institutions, notably the 
Ministry of Science and Technology (Ministério de Ciência e 
Tecnologia, MCT) and the state research support foundations 
(Fundação de Apoio à Pesquisa, FAP). The actions were guided 
by a conceptual framework in which there was an effort to trans-
late these findings into explicit policy formulations for SUS. 
The National Policy for Science, Technology and Innovation 
in Healthcare and the National Agenda of Priorities in Health-
care Research (Agenda Nacional de Prioridades de Pesquisa em 
Saúde, ANPPS) were agreed upon and established through a 
democratic process involving participation by government offi-
cials, researchers, healthcare managers and SUS clients during 
the Second National Conference on Science, Technology and 
Innovation in Healthcare.3 
The National Agenda was organized into 24 sub-agendas, 
and one of these was dedicated to “clinical research”. This sub-
agenda was organized into two sections. The first was broad, and 
dealt with “General development of clinical research”, including 
the following items: evaluation of diagnostic methods for ther-
apeutic interventions with new technologies and their applica-
bility; clinical trials on diagnostic and therapeutic procedures 
originating from national research; and studies to draw up and 
validate clinical protocols, including those for homeopathic 
and acupuncture treatments.4 The other section described some 
“Specific themes”, as follows: (i) clinical diagnostic study of con-
genital diseases, including kinship analysis; (ii) identification of 
genes, genetic polymorphism and compilation of a genetic data-
base; (iii) clinical evaluation of new generic drugs; (iv) clinical 
trials on substitutes for high-priced imported drugs or medical 
devices; (v) clinical trials on complementary therapeutic prac-
tices, such as using acupuncture in addition to the usual care 
to help lessen pain; (vi) clinical evaluation of long-term medi-
cation for the most prevalent conditions; (vii) preclinical and 
clinical research on medicinal plants, phytotherapeutic and bio-
active products traditionally used by the population; (viii) cell 
therapy, stem cells and pharmacogenetics; (ix) application of 
molecular biology techniques to diagnoses (like serum tests); 
and (x) clinical evaluation of interventions within physiother-
apy, occupational therapy and speech therapy.4 
The National Clinical Research Network
Over the last decade, a large number of clinical research proto-
cols have been in progress in Brazil, but the vast majority reflected 
the priorities of the private laboratories that commissioned them, 
without devoting space to SUS priorities. The participation of 
Brazilian researchers was usually restricted to gathering data and 
running protocols developed in other countries, while analysis 
and ownership of the data were left entirely to the commission-
ing companies. Establishment of a clinical research network was 
devised to place the country in a situation of greater autonomy 
to develop its own strategic clinical investigations. Considering 
the priority attributed to the national industrial policy and the 
need to encourage national production of drugs, vaccines, diag-
nostic kits and medical devices, it was necessary to develop clini-
cal research platforms. 
Within this context, the National Clinical Research Network 
(Rede Nacional de Pesquisa Clínica, RNPC) was created in 2005, 
through a Decit initiative, co-financed by the Financier of Stud-
ies and Projects (Financiadora de Estudos e Projetos/Ministério 
da Ciência e Tecnologia, FINEP/MCT), in order to establish a 
model for clinical research directed towards meeting the needs of 
SUS. The importance of encouraging and supporting this clini-
cal research network in teaching hospitals lay in the possibility of 
bringing together national reference centers and experts on cer-
tain research topics and procedures. This enabled the coopera-
tion necessary to leverage and accelerate a return of benefits to 
society through increased knowledge, techniques and products 
that met the population’s healthcare requirements and strength-
ened the health technology industrial sector.
Currently, the RNPC is composed of 32 clinical research 
centers linked to universities spread across the country’s five 
geographical regions.5 The Ministry of Health’s strategy was 
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to create a network aimed primarily at promoting the imple-
mentation of all phases of clinical trials on drugs, procedures, 
equipment, medical devices and new diagnostic methods that 
were of interest to SUS.5 The RNPC undertakes various actions 
to promote research and contributes to the development of 
human resources, through offering training courses on clinical 
research. During the five years since its inception, the network 
has promoted a great amount of cooperation and exchange. The 
greater proximity of research centers has allowed the RNPC to 
promote transfers of technology and knowledge between the 
research centers and to develop multicenter studies of relevance 
to the technical and scientific development of SUS, while always 
guided by the ANPPS. 
Definitions of Clinical Research
There are several characterizations of clinical research within the 
healthcare literature. The publication resulting from the Second 
National Conference on Science, Technology and Innovation in 
Healthcare defined clinical research as the type of research that 
follows the scientific methodology applicable to humans, known 
as volunteers or “research subjects”, who may be healthy or sick, 
according to the aims of such studies.6
The Association of American Medical Colleges Task Force on 
Clinical Research has also adopted a broad definition of the term: 
“a component of medical and health research intended to pro-
duce knowledge essential for understanding human disease, pre-
venting and treating illness and promoting health”.7 
The European Medicines Agency (EMEA) has defined clin-
ical research as “research on humans, in order to discover or 
verify the pharmacodynamic, pharmacological, clinical and/or 
other effects of the product and/or identify adverse reactions to 
the product under investigation, with the purpose of ascertaining 
its safety and/or efficacy”.8 
Some authors have introduced the term expanded clini-
cal research. This type of research activity aims to develop new 
knowledge and technologies for prevention and diagnosis of dis-
ease, and for treatment and rehabilitation of patients; innovations 
in the provision of healthcare and surveillance services; anthro-
pological studies; new approaches in providing care, surveillance 
and rehabilitation; and interdisciplinary approaches towards 
emerging diseases, among others.9 The diverse definitions for the 
term clinical research have to be borne in mind when analyzing 
clinical investigations developed in Brazil. 
METHODS
This empirical study was based on secondary data obtained 
from the Decit management database system (PesquisaSaúde).10 
The system provides information about projects funded by 
the Ministry of Health and its partners: the MCT, FAPs and 
National Bank for Economic and Social Development (Banco 
Nacional de Desenvolvimento Econômico e Social, BNDES). 
The electronic search covered the years 2002 to 2009, using the 
key word “clinical research” in the fields “primary sub-agenda” 
or “secondary sub-agenda”. Projects in the database were clas-
sified as “clinical research” either by the principal investiga-
tor (PI) of the project or by Decit staff. The process retrieved 
368 projects, for which the following information was avail-
able: title, abstract, key words, type of research, nature and 
sector of application, PI name and institution, year, resources 
approved, types of support, etc. 
The projects were then sorted into the following categories: 
(a) Basic biomedical research, which included experimental 
or theoretical studies that contribute towards understanding 
phenomena and observable facts or theories, without immedi-
ate use or application;11 (b) Preclinical studies, corresponding 
to application of new molecules in animals, after in vitro tri-
als have shown therapeutic potential, in order to obtain prelim-
inary information on the pharmacological activity and safety 
of these new molecules; this type of study would also be used 
to evaluate equipment or healthcare devices on animals;12 (c) 
Expanded clinical research, as defined by Marzochi9, except 
for clinical trials, which were analyzed in a separate category; 
(d) Clinical trials, including randomized clinical trials (RCTs), 
which are conducted mainly in developing new drugs,13 and are 
classified into four stages (I to IV);14 (e) Infrastructure sup-
port, which was fundamental for setting up the National Clini-
cal Research Network; and (f) Health technology assessment 
(HTA) projects. Some projects were not classified into these 
categories, due to insufficient information. 
The results obtained through some research projects funded 
by DECIT are concisely presented throughout the text, in order to 
illustrate the range of projects funded by the Ministry of Health, 
within the contexts of SUS and the ANPPS. 
A structured review was conducted by searching Medline 
and Embase from 2005 until July 21, 2011. The query “(“clinical” 
AND “research” AND “funding”)” yielded 680 articles. The titles 
and abstracts were manually inspected for relevance; 56 papers 
were acquired and carefully examined; 11 published papers were 
used in this review. Some results relating to clinical research 
funding in two developed countries (United States and United 
Kingdom) and four developing countries (Russia, India, China 
and South Africa, which together with Brazil form the BRICS 
group) are presented and discussed.   
RESULTS 
An amount of almost R$ 140 million was assigned to 368 proj-
ects over the course of the time period studied. Table 1 sum-
marizes the investments made by Decit and partners within the 
field of clinical research. National Calls for Proposals was the 
mechanism most used, followed by state calls. The meritocratic 
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open bidding process predominated, accounting for 97% of all 
the projects financed. Only 12 strategic projects were contracted 
without bids. The average investment was higher in the national 
Calls for Proposals, because this category included most of the 
clinical trials and all of the infrastructure projects. 
We retrieved 368 projects from the database, but 15 were 
impossible to categorize; the remaining 353 were classified into 
six categories (Table 2). Although the largest number of proj-
ects was found in the group Basic biomedical research (n = 118), 
the highest amount of investment was directed towards financ-
ing clinical trials (R$ 44 million) and infrastructure projects 
(R$ 37 million). However, from analyzing the amount allocated 
per project, infrastructure came first, with about R$ 1.5 million 
invested per clinical research center, and clinical trials came next, 
with an average of R$ 0.84 million per investigation. 
We concluded that the projects supported over the report-
ing period covered almost 94% of the topics included in the 
ANPPS clinical research sub-agenda previously described.4 The 
fields without financial support were those relating to: (v) clini-
cal trials on complementary therapeutic practices, such as acu-
puncture; (vi) clinical evaluation of long-term medication for the 
most prevalent conditions; and (x) clinical evaluation of inter-
ventions within occupational therapy and speech therapy. This 
may have been due to a scarcity of research groups dedicated to 
these fields in Brazil. 
Figure 1 shows the proportions of projects distributed 
according to geographical region; the southeastern region had the 
greatest proportion of the projects (49%) and financial resources 
(58%). This can be explained by the greater research tradition and 
larger number of qualified investigators in this region. Figure 2 
shows the trend over the years. The higher proportion of proj-
ects in 2005 correlated with the creation of the RNPC, which had 
the mission of decentralizing clinical research in Brazil, among 
other objectives. 
Another point worth noting is that the RNPC provides the 
opportunity to train new investigators. During the period ana-
lyzed, the 368 projects financed by the Ministry of Health and its 
partners contributed 575 high-level professionals trained in clin-
ical investigation at postgraduate level. These funds made it pos-
sible to produce 373 master dissertations and 203 doctoral theses, 
concluded between 2002 and 2009. 
Description
Type of financial support and selection process
State-level calls for proposals National calls for proposals Direct contracts Total
Number of projects 144 212 12 368
Investments (R$) R$ 11,743,849.65 R$ 123,039,840.20 R$ 4,586,960.47 R$ 139,370,650.30
Investment per project (R$) R$ 81,554.51 R$ 580,376.60 R$ 382,246.71 R$ 378,724.59










Funds invested  
per project (R$)
Basic biomedical 118 32.1% 22,026,573.30 15.8% 186,665.88
Preclinical 58 15.8% 10,337,452.40 7.4% 178,231.94
Expanded clinical 99 26.9% 18,931,425.74 13.6% 191,226.52
Clinical trials 53 14.4% 44,480,371.51 31.9% 839,252.29
Infrastructure 24 6.5% 37,339,604.73 26.8% 1,555,816.86
HTA projects* 1 0.3% 386,851.52 0.3% 386,851.52
Not classified 15 4.1% 5,868,371.12 4.2% 391,224.74
Total 368 100% 139,370,650.32 100% 378,724.59
Table 2. Investments by the Ministry of Health and its partners in clinical investigations and infrastructure for clinical research, according 
to project category. Brazil, 2002-2009 
HTA = Health Technology Assessment; *HTA projects are classified in a specific HTA sub-agenda; over the study period, 294 HTA projects were financed, which, 
however, are beyond the scope of the present study.
Figure 1. Investments by the Ministry of Health and its partners in 
clinical investigations and infrastructure for clinical research, according 
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 DISCUSSION
According to Zago, clinical research is an important tool for 
decision-making and aids in formulating health policies. How-
ever, Brazil needed to acquire its own data in order to formulate 
national public policies and solve the country’s specific problems.15 
Not coincidentally, the expansion in clinical research matches 
the actions taken by the Ministry of Health regarding financing 
for infrastructure and organizing the RNPC. The creation of the 
RNPC demonstrates the government’s commitment to developing 
health science and technology activities in this country. Develop-
ment of a network followed the constitutional guidance based on 
the three principles of universality, comprehensiveness and equity. 
It required effective involvement of clinical research teams with 
priorities as established in the National Health Plan.2 
Neglected tropical diseases are primarily infectious diseases 
that thrive in impoverished settings, especially in the heat and 
humidity of tropical climates. More than one billion people, rep-
resenting one-sixth of the world population, are infected with one 
or more of these diseases, which usually have very low priority in 
national healthcare programs.16 In Brazil, however, they deserve 
special attention from researchers and healthcare policymakers.17 
The RNPC supports the clinical trials necessary for producing new 
national pharmaceuticals, principally those relating to neglected 
diseases. It is very important for the RNPC to promote scientific 
knowledge, thus meeting the demands of public concerns.17
In 2007 and 2008, the Ministry of Health, together with the 
MCT, financed clinical research projects to be carried out in insti-
tutions belonging to the RNPC, through public bidding, empha-
sizing those relating to the following topics: diabetes, cardiovas-
cular disease, obesity, leishmaniasis, sleep apnea, osteoporosis 
and leprosy.
Many projects have already achieved interesting results. 
Recently, a clinical trial supported by the Ministry of Health 
showed promising results relating to the treatment of dermato-
logical manifestations of Leishmania braziliensis infection. This 
randomized clinical trial indicated that after six months of treat-
ment, the oral drug was more effective than the traditional anti-
mony injections, with regard to clinical remission and treatment 
compliance, although having a similar incidence of side effects.18 
Another study, conducted in Minas Gerais, focused on finding 
genetic polymorphisms associated with Chagas myocardiopathy. 
It found an association between interleukin-10 (IL-10) 1082G/A 
polymorphism and susceptibility to Chagas cardiomyopathy. This 
polymorphism was correlated with lower expression of IL-10, 
which was associated with worse cardiac function, as determined 
by left ventricular ejection fraction values in the study.19 
A preclinical trial supported by the Ministry of Health showed 
that a protein derived from Carica candamarcensis in experi-
mental rodent models presented mitogenic and healing proper-
ties.20 These proteins were previously patented by the research 
group as mitogenic proteases. Currently, the Ministry of Health 
is continuing to support the clinical stages of this study.
During the 2009 influenza A pandemic, the Ministry of 
Health decided to invest in strategic research in order to face up 
to the sanitary emergency better. Seven projects were financed, 
including investments in essential innovations for surveillance of 
influenza A. Most of the projects have already produced results. 
Initially, Brazil, as well as most countries, was totally dependent 
on inputs and reagents obtained from the United States Centers 
for Disease Control for the diagnostic kits. However, the “Nation-
alization of biotechnological products for molecular diagnosis 
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Figure 2. Annual investments made by the Ministry of Health and its partners in clinical investigations and infrastructure for clinical 
research, Brazil, 2002-2009.
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months later, the investigators launched the National Diagnostic 
Kit, thereby promoting access to inputs from molecular biology 
to achieve diagnostic tests for the influenza A pandemic virus. 
Moreover, biotechnological platforms have been deployed in 
three key national reference laboratories for influenza and three 
public health laboratories; equipment maintenance and human 
resources technical training has also been ensured.21
The results described here demonstrate the Ministry of Health’s 
progressive advances as a sponsor and key stakeholder in imple-
mentation and promotion of clinical research directed towards 
Brazil’s national requirements, largely due to creation of the RNPC. 
Future healthcare policies should promote democratization of the 
clinical research funding processes in order to decentralize research 
investments throughout the country. Currently, many clinical stud-
ies are taking place through the RNPC and their conclusions will 
help to improve the Brazilian public health system.
Recently, a study showed how different research fields are priori-
tized for NIH (National Institutes of Health) support.22 The authors 
concluded that, in 2006, the levels of disease-specific funding corre-
lated only modestly with the burden of disease in the United States, 
and the correlation had not improved in relation to 1996 levels. The 
conditions receiving the most funding were AIDS and diabetes while 
on the other hand, the least amount of funding, relative to the bur-
den of disease, was destined for depression and injuries.22
Funding for practice-oriented clinical research in the United 
Kingdom was considered insufficient in 2006.23 Biomedical and 
etiological research, which was mostly laboratory-based, spent 
from 60% to 90% of the budget allocations from four major fund-
ing institutions in the United Kingdom. Important topics such 
as prevention, detection and diagnosis, treatment development 
and evaluation, disease management and health service research 
received only a small fraction of the funds.23 More recently, 
another author expressed the opinion that overregulation of clin-
ical research in Britain had led to decreased numbers of ongoing 
clinical trials.24 The British National Institute for Health Research 
had built a sustainable infrastructure to support clinical research 
for patients’ benefit. However, while the safety and interests of 
patients were protected, clinical research in the United King-
dom had become unnecessarily stifled by incremental bureau-
cratic arrangements. The British Academy of Medical Sciences 
was consulted to make recommendations with the aim of opti-
mizing clinical research. They suggested that a National Research 
Governance Service, responsible for centralizing ethical reviews 
of protocols and project monitoring, should be created.24 
In some respects, clinical research in Brazil compares favorably 
with the situation in other BRICS countries. Clinical research in 
Russia was on the rise over the last decade, thus leading to optimism 
about attainment of Russia’s potential to undertake clinical trials.25 
However, in 2007, the Federal Customs Service completely blocked 
the exportation of all human biological materials from Russia, from 
hair to tissue and blood samples, thereby threatening dozens of clin-
ical trials, under the suspicion of “involvement of Western institu-
tions in the development of genetic weapons against Russia”.26   
Serious concerns have been raised about ethical issues relat-
ing to clinical trials conducted in India and the local ethics com-
mittees’ lack of independence.27,28 A recent investigation revealed 
at least four trials, run by large pharmaceutical companies, which 
violated the Indian Medical Research Council’s ethical guidelines 
and the World Medical Association’s Declaration of Helsinki.28 
With a huge population, a plethora of diseases and rampant pov-
erty, India is considered to be an “irresistible” location for clini-
cal trials.29 Pharmaceutical industry giants are attracted to India 
because of its 700,000 specialty hospital beds, 221 medical col-
leges and skilled English-speaking medical personnel. However, 
the biggest advantage is the low cost: trials for a standard drug in 
the United States can cost about $150 million and a similar drug 
could be tested in India at a 60% lower cost.29
The status of clinical research in China was recently 
reviewed.30 The authors showed that the numbers of clinical trials 
and published papers in global first-class journals had increased 
over the period under review (2000-2009). The number of RCTs 
conducted in China increased from 85 in 2000 to 743 in 2009, 
and constituted nearly a third of the total number of published 
clinical research papers in China. Out of the 2,500 Chinese phy-
sicians interviewed, only a minority had reasonable knowledge 
about clinical research. However, most of them mentioned that 
there was a need for research in this field and expressed willing-
ness to participate in clinical trials. The authors concluded that 
China still needed to step up its efforts in many respects, in order 
to promote the development of clinical research.30
From South Africa, there has been a report on how the lack 
of investment in the field reduced the number of projects running 
and articles published between 1980 and 2009.31 The South African 
Medical Research Council, which falls under the country’s Depart-
ment of Health, has failed so far to link itself to these important and 
highly effective investments.31 A survey on how to improve clini-
cal research was conducted, based on interviews with senior deci-
sion-makers at institutions with stakes in the South African public 
sector clinical trial research environment.32 There was a consensus 
regarding the need to establish a sustainable national clinical trial 
support initiative. An agency with this mission should be respon-
sible for funding, staffing, making quality controls, monitoring and 
overseeing approved clinical trials.32 
One successful experience in this direction was the estab-
lishment of the National Clinical Research Network in Brazil. A 
leading Brazilian scientist in this field stated that: “The leader-
ship exerted by the Ministry of Health with regard to equip-
ping teaching hospitals to develop quality clinical research is 
clear. The creation of the RNPC, with funding for infrastruc-
ture and development of appropriate multicenter projects of 
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interest to SUS, has been contributing decisively towards rec-
ognition and institutionalization of clinical research in this 
country’s teaching hospitals”.2
CONCLUSION
The Ministry of Health’s strategy of creating the RNPC brought 
together the partners needed to build a new model for clinical 
research, dedicated to the real needs of SUS. Through seeking to 
consolidate this network, priority has been given to standardiza-
tion and implementation of all phases of clinical trials on drugs, 
procedures, equipment, medical devices and new diagnostic 
methods. The “PesquisaSaúde” research management database 
is an important tool for registering the government’s actions, 
thereby ensuring that the research is completely accessible to all 
those involved in healthcare decision-making, with improved 
research transparency and strengthening of the value of evi-
dence-based decisions. The investments have ensured that clini-
cal research in Brazil has been strengthened, through adequate 
infrastructure, researchers with highly professional qualifications 
and an increased link between teaching and research. Ministry of 
Health actions have ensured cohesion between health policies, 
knowledge production and the healthcare industrial sector. 
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